Your browser is no longer supported. Please, upgrade your browser.
Settings
BGNE BeiGene, Ltd. daily Stock Chart
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-12.75 Insider Own0.10% Shs Outstand59.60M Perf Week1.35%
Market Cap7.41B Forward P/E- EPS next Y-12.11 Insider Trans-67.33% Shs Float59.13M Perf Month3.71%
Income-735.30M PEG- EPS next Q-3.12 Inst Own82.70% Short Float6.86% Perf Quarter3.81%
Sales243.50M P/S30.44 EPS this Y-460.00% Inst Trans0.04% Short Ratio14.75 Perf Half Y-11.99%
Book/sh26.99 P/B4.61 EPS next Y8.20% ROA-34.70% Target Price181.39 Perf Year-24.65%
Cash/sh27.08 P/C4.59 EPS next 5Y24.00% ROE-45.10% 52W Range105.19 - 194.56 Perf YTD-11.34%
Dividend- P/FCF- EPS past 5Y- ROI-35.50% 52W High-33.14% Beta1.03
Dividend %- Quick Ratio7.50 Sales past 5Y77.80% Gross Margin83.80% 52W Low23.67% ATR4.62
Employees2400 Current Ratio7.50 Sales Q/Q139.40% Oper. Margin- RSI (14)60.25 Volatility3.63% 3.62%
OptionableYes Debt/Eq0.15 EPS Q/Q-38.70% Profit Margin- Rel Volume0.94 Prev Close124.36
ShortableYes LT Debt/Eq0.14 EarningsAug 08 AMC Payout- Avg Volume274.95K Price130.09
Recom1.60 SMA204.52% SMA504.59% SMA200-0.53% Volume112,699 Change4.61%
Jun-04-19Initiated Bernstein Outperform $201
May-10-19Upgrade CLSA Outperform → Buy
Mar-15-19Initiated BofA/Merrill Buy $200
Jan-04-19Downgrade CLSA Buy → Outperform
Nov-21-18Initiated JP Morgan Overweight $174
Sep-25-18Initiated Leerink Partners Outperform
May-17-18Reiterated Maxim Group Buy $200 → $225
May-14-18Initiated Credit Suisse Outperform
Apr-13-18Initiated Piper Jaffray Overweight $200
Apr-10-18Reiterated Maxim Group Buy $160 → $200
Mar-01-18Reiterated Maxim Group Buy $144 → $160
Nov-14-17Downgrade Robert W. Baird Outperform → Neutral $58 → $83
Sep-28-17Reiterated Maxim Group Buy $77 → $120
Aug-07-17Initiated Ladenburg Thalmann Buy $81
Jul-06-17Reiterated Maxim Group Buy $57 → $73
Jul-05-17Reiterated Maxim Group Buy $52 → $57
Sep-22-16Initiated Maxim Group Buy $41
Feb-29-16Initiated Robert W. Baird Outperform $44
Feb-29-16Initiated Morgan Stanley Overweight
Feb-29-16Initiated Goldman Buy $33
Jul-15-19 12:27PM  Did You Miss BeiGene's (NASDAQ:BGNE) Whopping 327% Share Price Gain? Simply Wall St.
Jul-12-19 12:33PM  Here's Why BeiGene Lost 11.6% in the First Half of 2019 Motley Fool
Jul-09-19 07:00AM  3 Top Chinese Stocks to Watch in July Motley Fool
Jul-07-19 08:00PM  Priority Review Granted to BeiGenes Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma GlobeNewswire
Jun-28-19 09:25AM  BeiGene Granted Approval to Transition from the Biotech Chapter of the Hong Kong Stock Exchange to a General Listing GlobeNewswire
Jun-26-19 05:40PM  The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far) Motley Fool
Jun-25-19 09:45PM  Heres What Hedge Funds Think About BeiGene, Ltd. (BGNE) Insider Monkey
Jun-20-19 11:05AM  BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML) GlobeNewswire
07:45AM  BeiGene Presents Pivotal Phase 2 Clinical Results of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML) GlobeNewswire
Jun-19-19 11:21AM  BeiGene Announces Updated Results from Two Ongoing Clinical Trials of Zanubrutinib in Patients with Mantle Cell Lymphoma in Presentations at the 15th International Conference on Malignant Lymphoma (ICML) GlobeNewswire
Jun-18-19 07:00AM  BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor GlobeNewswire
Jun-17-19 07:00AM  BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab GlobeNewswire
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-14-19 02:30AM  BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA) GlobeNewswire -5.97%
02:30AM  BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA) GlobeNewswire
Jun-12-19 04:00AM  BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML) GlobeNewswire
Jun-11-19 11:20AM  Is BeiGene, Ltd. (NASDAQ:BGNE) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Jun-05-19 07:00AM  BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
Jun-04-19 09:25AM  BeiGene Chief Executive Officer John V. Oyler Elected to BIO Board of Directors GlobeNewswire
Jun-01-19 09:00AM  BeiGene Announces Preliminary Phase 2 Results of Tislelizumab in Chinese Patients with Nasopharyngeal Cancer at the 2019 ASCO Annual Meeting GlobeNewswire
May-31-19 07:34AM  The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering Benzinga
May-30-19 07:00PM  BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer GlobeNewswire
07:00PM  BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma GlobeNewswire
May-16-19 09:00AM  BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association GlobeNewswire
May-09-19 08:01PM  BRIEF-Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million Reuters
04:35PM  BRIEF-BeiGene Q1 Loss Per Share $0.22 Reuters
04:05PM  BeiGene Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-30-19 07:30AM  Is BeiGene, Ltd. (NASDAQ:BGNE) Trading At A 24% Discount? Simply Wall St.
Apr-29-19 06:34AM  BRIEF-Beigene Ltd Says CEO's Total Compensation For FY 2018 Was $27.9 Mln Versus $10.3 Mln In FY 2017 Reuters +6.24%
Apr-09-19 01:54PM  Heres What Hedge Funds Think About BeiGene, Ltd. (BGNE) Insider Monkey
06:05AM  BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy GlobeNewswire
Apr-03-19 04:41AM  Micron Technology, Tencent and two dozen other companies most likely to benefit from a China trade deal MarketWatch
Apr-01-19 04:05PM  BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting GlobeNewswire
Mar-30-19 09:28AM  Does BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Pay Matter? Simply Wall St.
Mar-22-19 03:48PM  3 Key Takeaways From BeiGene's CEO Motley Fool -8.90%
Mar-09-19 08:55AM  Be cautious about the market now and buy these 3 stocks on weakness MarketWatch
Mar-06-19 07:10AM  BRIEF-Ambrx And Beigene Announce Global Research And Development Collaboration To Develop Next-Generation Biologics Reuters
07:00AM  Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics GlobeNewswire
Mar-05-19 08:35AM  Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-04-19 07:00AM  BeiGene to Present at Upcoming Investor Conferences GlobeNewswire
Mar-03-19 08:00PM  Edited Transcript of BGNE earnings conference call or presentation 27-Feb-19 11:00pm GMT Thomson Reuters StreetEvents
Mar-01-19 11:59AM  Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018 Zacks +10.40%
09:16AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4 Zacks
Feb-28-19 11:12AM  Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat Zacks
Feb-27-19 04:28PM  BRIEF-Beigene Reports Qtrly Loss Per Share Of $0.35 Reuters
04:15PM  BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
04:00PM  BeiGene Ltd. Sponsored ADR to Host Earnings Call ACCESSWIRE
Feb-22-19 07:00AM  BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-21-19 09:35AM  Have Insiders Been Selling BeiGene, Ltd. (NASDAQ:BGNE) Shares? Simply Wall St.
Feb-19-19 04:30PM  BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma GlobeNewswire +5.07%
08:30AM  Market Trends Toward New Normal in CenturyLink, Textainer Group, BeiGene, Nova Measuring Instruments, One Liberty Properties, and Westwood Holdings Group Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-18-19 09:14AM  BeiGene, Ltd. (BGNE) Upgraded to Strong Buy: Here's What You Should Know Zacks
Feb-13-19 04:30PM  BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong GlobeNewswire
Feb-07-19 07:00AM  BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum Oncology Day GlobeNewswire
Jan-21-19 10:00AM  BeiGene, Ltd. (BGNE) Is Up 12.82% in One Week: What You Should Know Zacks
Jan-17-19 03:07PM  6 Stocks Beating the Market GuruFocus.com
Jan-14-19 05:17PM  BRIEF-Beigene Receives U.S. FDA Breakthrough Therapy Designation For Zanubrutinib Reuters
04:41PM  BRIEF-Beigene Receives FDA Breakthrough Therapy Designation For Zanubrutinib In Mantle Cell Lymphoma Reuters
04:36PM  BeiGene drug gets 'breakthrough therapy' designation from FDA MarketWatch
04:15PM  BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma GlobeNewswire
Jan-11-19 08:00PM  Engaged Capital Helps Rethink Benchmark Electronics Barrons.com
Jan-03-19 04:49PM  BRIEF-Hillhouse Capital Management Ltd Reports 1.7 Pct Stake In Beigene Ltd Reuters -5.68%
11:01AM  Here's Why BeiGene Is Taking a Hit Today Motley Fool
07:00AM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-24-18 09:37AM  Don't Miss Chinese Biotechs Motley Fool
Dec-21-18 12:00AM  Our Top Stock Idea in Chinas Biotech Revolution Motley Fool
Dec-20-18 02:40PM  Has BeiGene, Ltd. (NASDAQ:BGNE) Got Enough Cash? Simply Wall St.
Dec-17-18 06:28AM  BRIEF-Beigene Initiates Two Global Phase 3 Front-Line Clinical Trials Of Tislelizumab Reuters
06:00AM  BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer GlobeNewswire
Dec-15-18 02:30AM  BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress GlobeNewswire
Dec-12-18 12:38AM  Is BeiGene, Ltd. (BGNE) Going to Burn These Hedge Funds? Insider Monkey
Dec-10-18 06:05AM  BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress GlobeNewswire
Dec-09-18 04:46PM  Here's Why BeiGene Stock Rose 21.7% in November Motley Fool
Dec-05-18 07:00AM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-03-18 02:15PM  BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkins Lymphoma at the 60th American Society of Hematology Annual Meeting GlobeNewswire
Dec-01-18 03:45PM  BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting GlobeNewswire
Nov-30-18 04:05PM  Chinese biotech stocks hit by a double whammy, which means its time to buy MarketWatch +6.53%
06:06AM  Can The Uptrend Continue for BeiGene (BGNE)? Zacks
Nov-28-18 09:00AM  Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
08:39AM  Earnings Estimates Moving Higher for BeiGene (BGNE): Time to Buy? Zacks
Nov-27-18 06:58AM  BRIEF-Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates Reuters
06:30AM  Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks Azymetric and EFECT Platforms Globally Business Wire
Nov-21-18 02:53PM  Analysts Take Action on Health Care Stocks GuruFocus.com
Nov-20-18 07:00AM  BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-16-18 07:00AM  BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology GlobeNewswire
Nov-15-18 08:54AM  BeiGene (BGNE) Catches Eye: Stock Jumps 8.3% Zacks
07:00AM  Priority Review Granted to BeiGenes New Drug Applications for Zanubrutinib and Tislelizumab in China GlobeNewswire
Nov-13-18 07:00AM  BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-08-18 04:32PM  Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors PR Newswire
Nov-07-18 05:36PM  BRIEF-Beigene Initiates Global Head-To-Head Phase 3 Clinical Trial Of Zanubrutinib Reuters
07:00AM  BeiGene Reports Third Quarter 2018 Financial Results GlobeNewswire
07:00AM  BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma GlobeNewswire
Nov-05-18 07:00AM  BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology GlobeNewswire
Nov-02-18 04:11AM  Chinas Innovent Extends Gain from Solid HK IPO Investing.com
Nov-01-18 09:00AM  BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Gilead Sciences and BeiGene ACCESSWIRE
Oct-24-18 07:05AM  BRIEF-Beigene Announces Acceptance Of Its New Drug Application In China Reuters -5.82%
07:00AM  BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma GlobeNewswire
Oct-22-18 08:49AM  BRIEF-Beigene Presents Preliminary Clinical Trial Data In Patients With Solid Tumors Reuters -5.86%
08:18AM  BeiGene (BGNE): Moving Average Crossover Alert Zacks
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; CC-122, a cereblon modulator; and BGB-3245, an oral small molecule inhibitor of specific BRAF mutations, including B-RAF non-V600 mutations and RAF fusions for various solid tumor indications. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the People's Republic of China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OYLER JOHNChief Executive OfficerJul 08Sale126.873,106394,0550Jul 09 07:23 PM
Wang XiaodongChair, Scientific Advisory BrdJul 01Sale126.464,847612,9370Jul 01 08:27 PM
Huang JaneCMO, HematologyJun 27Sale124.5243053,5420Jul 01 08:30 PM
Liang HowardCFO & Chief Strategy OfficerJun 27Sale9.475,87655,653122,317Jul 01 08:28 PM
Liang HowardCFO & Chief Strategy OfficerMay 21Option Exercise6.5023,200150,80023,200May 22 07:03 PM
Huang JaneCMO, HematologyMay 21Option Exercise45.312,20099,6822,200May 22 07:04 PM
Huang JaneCMO, HematologyMay 21Sale130.062,200286,1320May 22 07:04 PM
Liang HowardCFO & Chief Strategy OfficerMay 21Sale130.2123,2003,020,8600May 22 07:03 PM
Huang JaneCMO, HematologyMay 20Option Exercise45.3130013,593300May 22 07:04 PM
Huang JaneCMO, HematologyMay 20Sale130.1230039,0360May 22 07:04 PM
Glazer Donald W.DirectorMay 13Sale125.1115,0271,880,0280May 15 03:59 PM
Liang HowardCFO & Chief Strategy OfficerMay 06Option Exercise6.501,80011,7001,800May 08 05:53 PM
Liang HowardCFO & Chief Strategy OfficerMay 06Sale130.011,800234,0140May 08 05:53 PM
Wu XiaobinPresident & GM ChinaMay 01Sale124.525,955741,54617,365May 02 04:08 PM
OYLER JOHNChief Executive OfficerMay 01Sale125.182,824353,5050May 02 04:07 PM
Huang JaneCMO, HematologyApr 08Option Exercise29.4914,130416,69414,130Apr 10 06:41 PM
Huang JaneCMO, HematologyApr 08Sale142.7714,1302,017,3150Apr 10 06:41 PM
Glazer Donald W.DirectorMar 14Sale136.1014,9732,037,8250Mar 18 06:30 PM
Huang JaneCMO, HematologyMar 11Option Exercise29.492,56575,6422,565Mar 11 07:38 PM
Huang JaneCMO, HematologyMar 11Sale130.002,565333,4500Mar 11 07:38 PM
Huang JaneCMO, HematologyMar 07Sale140.50719,9760Mar 11 07:38 PM
OYLER JOHNChief Executive OfficerMar 06Sale150.0010015,000100Mar 06 06:32 PM
OYLER JOHNChief Executive OfficerMar 05Sale151.766,230945,4540Mar 06 06:32 PM
OYLER JOHNChief Executive OfficerMar 05Sale152.254,791729,4330Mar 06 06:32 PM
OYLER JOHNChief Executive OfficerMar 04Sale151.349,7901,481,6250Mar 06 06:32 PM
OYLER JOHNChief Executive OfficerMar 04Sale152.014,588697,4260Mar 06 06:32 PM
Peterson Amy C.CMO, Immuno-oncologyDec 18Option Exercise29.1010,141295,10310,141Dec 19 06:34 PM
Peterson Amy C.CMO, Immuno-oncologyDec 18Sale133.7510,1411,356,3120Dec 19 06:34 PM
Peterson Amy C.CMO, Immuno-oncologyDec 17Option Exercise29.109,859286,8979,859Dec 19 06:34 PM
Peterson Amy C.CMO, Immuno-oncologyDec 17Sale133.619,8591,317,2240Dec 19 06:34 PM
OYLER JOHNChief Executive OfficerDec 10Sale135.784,138561,8630Dec 12 05:28 PM
Wang XiaodongDirectorDec 03Sale152.415,000762,0610Dec 04 05:35 PM
OYLER JOHNChief Executive OfficerNov 28Sale147.198,8651,304,8624,138Nov 28 07:26 PM
OYLER JOHNChief Executive OfficerNov 27Sale144.5711,2521,626,74313,003Nov 28 07:26 PM
Huang JaneCMO, HematologyNov 26Option Exercise29.493,00088,4703,000Nov 28 07:25 PM
OYLER JOHNChief Executive OfficerNov 26Sale139.069,0781,262,43024,255Nov 28 07:26 PM
Huang JaneCMO, HematologyNov 26Sale139.583,000418,7500Nov 28 07:25 PM
Wang XiaodongDirectorNov 19Sale124.305,000621,4900Nov 21 06:41 PM
Peterson Amy C.CMO, Immuno-oncologyNov 12Option Exercise29.1012,067351,15012,067Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 12Sale112.7312,0671,360,3490Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 09Option Exercise29.1013,222384,76013,222Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 09Sale120.4913,2221,593,1630Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 08Option Exercise29.1014,711428,09014,711Nov 13 10:20 AM
Peterson Amy C.CMO, Immuno-oncologyNov 08Sale126.0714,7111,854,5770Nov 13 10:20 AM
Huang JaneCMO, HematologySep 04Sale174.602,911508,2470Sep 05 05:15 PM
Glazer Donald W.DirectorAug 30Sale179.001,000179,00013,384Aug 31 04:54 PM
Glazer Donald W.DirectorAug 29Sale179.001,000179,00014,384Aug 31 04:54 PM
Peterson Amy C.CMO, Immuno-oncologyAug 23Sale169.125,769975,6660Aug 24 04:25 PM
Wang XiaodongDirectorAug 13Sale158.773,449547,5910Aug 15 04:23 PM
BAKER BROS. ADVISORS LPDirectorAug 02Buy108.005,814,100627,922,8005,250,491Aug 06 05:22 PM